Acadia Pharmaceuticals Inc.
ACAD Real Time Price USDRecent trades of ACAD by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ACAD holdings by institutional investors
Quarterly net insider trading by ACAD's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Oct 07, 2026 Issue: Taxation/Internal Revenue Code
-
$700,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$600,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$590,000 Jan 19, 2026 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
-
$750,000 Oct 19, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$500,000 Jul 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$440,000 Apr 18, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$510,000 Jan 19, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code
-
$220,000 Oct 21, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
-
$450,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$240,000 Jan 19, 2024 Issue: Medicare/Medicaid Health Issues
-
$180,000 Oct 18, 2023 Issue: Medicare/Medicaid Health Issues
-
$230,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$370,000 Jan 19, 2023 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
-
$260,000 Oct 19, 2022 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
-
$310,000 Aug 18, 2022 Issue: None
-
$230,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$200,000 Jan 20, 2022 Issue: None
-
$210,000 Oct 19, 2021 Issue: None
-
$210,000 Jul 19, 2021 Issue: None
-
$220,000 Apr 20, 2021 Issue: None
-
$190,000 Jan 20, 2021 Issue: None
-
$10,000 Oct 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$10,000 Jul 15, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Apr 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$20,000 Jan 21, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Oct 21, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Jul 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Apr 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Oct 22, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
Former government officials who have lobbied for ACAD
13 former government officials from 7 congressional offices at 5 lobbying firms have lobbied for ACAD, most recently Apr 16, 2026.
-
Alanna Temme House Legislative Director, U.S. Representative Jon Porter -
Darin Gardner Senate Legislative Correspondent to Senator Tim Hutchinson; Research Assistant for Senate HELP Committee; Chief of Staff for Congresswoman Kay Granger -
Andrew Siracuse Senate New Sr. Tax Cnsl., Sen. John Cornyn; Staff Dir., Sen. Fin. Cmte. Int'l. Trade, Customs & Global Comp. Sbcmte., Tax Cnsl., Sen. Cornyn; Cnsl. Sen. Cornyn; Staff Dir. Sen. Fin. Cmte, Energy, Nat. Res. Sbcmte.; LA, Sen. Cornyn; LA, Sen. Norm Coleman -
John Twomey House New Chief of Staff, HHS Office of the Asst. Sec. for Legislation (2019-2021); Policy Adviser, HHS (2017-2019); Special Asst., Office of the Secretary, HHS (2017); Staff Assistant, Rep. Tom Price (2015-2017); Intern, Rep. Doug Collins (2015) -
Joshua Odintz Senate New Tax Counsel, Senate Finance Committee
-
Bryan Shuy House New Chief of Staff Rep. Harris; Asst. to Rep. Harris, House Cmte on Approps; Dep. Asst. Sec and Chief of Staff HHS/Asst. Secretary for Preparedness and Response (ASPR)
-
Corey Malmgren Congress New Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010)
-
Bryant Hall Senate New Staff Director, Sen. Veterans Affairs Committee (2003-2004); Legislative Director, Sen. Bob Graham (1999-2003)
ACAD Estimated quarterly lobbying spending
ACAD Revenue by Segment or Geography
New ACAD patent grants
-
Patent Title: Single-layer oral dose of neuro-attenuating ketamine Feb. 24, 2026
-
Patent Title: Crystalline forms of trofinetide Dec. 09, 2025
-
Patent Title: Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods Nov. 11, 2025
-
Patent Title: Compounds, salts thereof and methods for treatment of diseases Nov. 12, 2024
-
Patent Title: Agitation process for preparing a carbetocin drug product Dec. 19, 2023
-
Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Dec. 12, 2023
-
Patent Title: Crystalline forms of trofinetide Nov. 28, 2023
-
Patent Title: Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis Oct. 11, 2022
-
Patent Title: Formulations of pimavanserin Sep. 27, 2022
-
Patent Title: Compounds, salts thereof and methods for treatment of diseases Sep. 13, 2022
-
Patent Title: Compounds, salts thereof and methods for treatment of diseases May. 31, 2022
-
Patent Title: Combination of pimavanserin and cytochrome p450 modulators Dec. 07, 2021
-
Patent Title: Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent Nov. 02, 2021
-
Patent Title: Pimavanserin for treating impulse control disorder Oct. 05, 2021
-
Patent Title: Compounds for pain treatment, compositions comprising same, and methods of using same Aug. 17, 2021
-
Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Apr. 20, 2021
-
Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form Apr. 20, 2021
-
Patent Title: Methods of treatment using selective 5-ht2a inverse agonists Sep. 19, 2017
-
Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 12, 2017
-
Patent Title: Muscarinic agonists Jun. 06, 2017
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 14, 2017
-
Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Dec. 20, 2016
-
Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 20, 2016
-
Patent Title: Azacyclic compounds Mar. 29, 2016
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 15, 2015
-
Patent Title: Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta Jun. 23, 2015
-
Patent Title: Combination of pimavanserin and risperidone for the treatment of psychosis Jun. 09, 2015
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 30, 2014
-
Patent Title: Compounds with activity at estrogen receptors Sep. 02, 2014
-
Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Mar. 25, 2014
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 31, 2013
-
Patent Title: Compounds with activity at estrogen receptors Jun. 25, 2013
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 19, 2013
-
Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Aug. 07, 2012
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jul. 24, 2012
-
Patent Title: Compounds with activity at estrogen receptors Jan. 24, 2012
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 30, 2011
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 09, 2011
-
Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Apr. 12, 2011
-
Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 25, 2011
-
Patent Title: Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-y1)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation Jan. 11, 2011
-
Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 04, 2011
-
Patent Title: Compounds with activity at estrogen receptors Nov. 02, 2010
-
Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Oct. 26, 2010
-
Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Sep. 07, 2010
-
Patent Title: N-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Jun. 08, 2010
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jun. 08, 2010
-
Patent Title: Spiroazacyclic compounds as monoamine receptor modulators Jun. 01, 2010
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases May. 11, 2010
-
Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 09, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ACAD from public contracts
Recent insights relating to ACAD
Recent picks made for ACAD stock on CNBC
ETFs with the largest estimated holdings in ACAD
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ACAD stock a Buy, Sell, or Hold?
- What is the price target for $ACAD stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ACAD stock?
- Who owns the most shares of $ACAD stock?
- What funds own $ACAD stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ACAD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Address San Diego, CA
- Market Cap 3.4 billion
- Employees 798
- Industrial Classification Pharmaceutical Preparations
Acadia Pharmaceuticals Inc. (ACAD) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Acadia Pharmaceuticals Inc. (ACAD).
Quiver Premium charts ACAD's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ACAD, per a recent SEC DEF 14A filing. We estimate that the median employee at ACADIA PHARMACEUTICALS INC is paid $340,972.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|